vs
Alphatec Holdings, Inc.（ATEC）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Alphatec Holdings, Inc.的1.0倍（$219.9M vs $212.9M），Orthofix Medical Inc.净利率更高（-1.0% vs -10.2%，领先9.2%），Alphatec Holdings, Inc.同比增速更快（20.4% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $7.7M），过去两年Alphatec Holdings, Inc.的营收复合增速更高（24.0% vs 8.0%）
Alphatec Holdings是一家全球医疗科技企业，专注于研发、生产及销售脊柱外科手术相关的植入物、手术器械与数字化手术平台，服务骨科及神经外科医疗从业者，核心市场覆盖北美、欧洲及亚太主要区域。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
ATEC vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.0倍
$212.9M
营收增速更快
ATEC
高出18.5%
2.0%
净利率更高
OFIX
高出9.2%
-10.2%
自由现金流更多
OFIX
多$9.1M
$7.7M
两年增速更快
ATEC
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $212.9M | $219.9M |
| 净利润 | $-21.7M | $-2.2M |
| 毛利率 | 70.2% | 71.1% |
| 营业利润率 | -4.1% | 0.2% |
| 净利率 | -10.2% | -1.0% |
| 营收同比 | 20.4% | 2.0% |
| 净利润同比 | 34.8% | 92.4% |
| 每股收益（稀释后） | $-0.15 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATECOFIX
| Q4 25 | $212.9M | $219.9M | ||
| Q3 25 | $196.5M | $205.6M | ||
| Q2 25 | $185.5M | $203.1M | ||
| Q1 25 | $169.2M | $193.6M | ||
| Q4 24 | $176.8M | $215.7M | ||
| Q3 24 | $150.7M | $196.6M | ||
| Q2 24 | $145.6M | $198.6M | ||
| Q1 24 | $138.5M | $188.6M |
净利润ATECOFIX
| Q4 25 | $-21.7M | $-2.2M | ||
| Q3 25 | $-28.6M | $-22.8M | ||
| Q2 25 | $-41.1M | $-14.1M | ||
| Q1 25 | $-51.9M | $-53.1M | ||
| Q4 24 | $-33.3M | $-29.1M | ||
| Q3 24 | $-39.6M | $-27.4M | ||
| Q2 24 | $-40.7M | $-33.4M | ||
| Q1 24 | $-48.5M | $-36.0M |
毛利率ATECOFIX
| Q4 25 | 70.2% | 71.1% | ||
| Q3 25 | 69.9% | 72.2% | ||
| Q2 25 | 69.6% | 68.7% | ||
| Q1 25 | 68.6% | 62.8% | ||
| Q4 24 | 68.8% | 69.0% | ||
| Q3 24 | 68.2% | 68.7% | ||
| Q2 24 | 70.5% | 67.8% | ||
| Q1 24 | 70.3% | 67.5% |
营业利润率ATECOFIX
| Q4 25 | -4.1% | 0.2% | ||
| Q3 25 | -8.1% | -8.3% | ||
| Q2 25 | -7.1% | -7.9% | ||
| Q1 25 | -26.2% | -25.2% | ||
| Q4 24 | -13.5% | -5.3% | ||
| Q3 24 | -22.4% | -9.6% | ||
| Q2 24 | -24.3% | -12.5% | ||
| Q1 24 | -31.3% | -15.6% |
净利率ATECOFIX
| Q4 25 | -10.2% | -1.0% | ||
| Q3 25 | -14.5% | -11.1% | ||
| Q2 25 | -22.2% | -6.9% | ||
| Q1 25 | -30.7% | -27.4% | ||
| Q4 24 | -18.9% | -13.5% | ||
| Q3 24 | -26.3% | -13.9% | ||
| Q2 24 | -27.9% | -16.8% | ||
| Q1 24 | -35.0% | -19.1% |
每股收益（稀释后）ATECOFIX
| Q4 25 | $-0.15 | $-0.05 | ||
| Q3 25 | $-0.19 | $-0.57 | ||
| Q2 25 | $-0.27 | $-0.36 | ||
| Q1 25 | $-0.35 | $-1.35 | ||
| Q4 24 | $-0.22 | $-0.76 | ||
| Q3 24 | $-0.28 | $-0.71 | ||
| Q2 24 | $-0.29 | $-0.88 | ||
| Q1 24 | $-0.34 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $160.8M | $82.0M |
| 总债务越低越好 | $565.9M | — |
| 股东权益账面价值 | $12.4M | $450.0M |
| 总资产 | $791.2M | $850.6M |
| 负债/权益比越低杠杆越低 | 45.54× | — |
8季度趋势，按日历期对齐
现金及短期投资ATECOFIX
| Q4 25 | $160.8M | $82.0M | ||
| Q3 25 | $155.7M | $62.9M | ||
| Q2 25 | $157.1M | $65.6M | ||
| Q1 25 | $153.2M | $58.0M | ||
| Q4 24 | $138.8M | $83.2M | ||
| Q3 24 | $81.0M | $30.1M | ||
| Q2 24 | $99.8M | $26.4M | ||
| Q1 24 | $144.1M | $27.0M |
总债务ATECOFIX
| Q4 25 | $565.9M | — | ||
| Q3 25 | $559.7M | $157.2M | ||
| Q2 25 | $553.9M | $157.0M | ||
| Q1 25 | $548.4M | $156.9M | ||
| Q4 24 | $576.2M | $157.0M | ||
| Q3 24 | $527.7M | $118.5M | ||
| Q2 24 | $519.2M | $118.0M | ||
| Q1 24 | $514.4M | $118.2M |
股东权益ATECOFIX
| Q4 25 | $12.4M | $450.0M | ||
| Q3 25 | $11.5M | $442.5M | ||
| Q2 25 | $23.8M | $458.3M | ||
| Q1 25 | $-85.9M | $458.3M | ||
| Q4 24 | $-14.2M | $503.1M | ||
| Q3 24 | $-1.4M | $525.9M | ||
| Q2 24 | $17.1M | $546.0M | ||
| Q1 24 | $37.6M | $570.3M |
总资产ATECOFIX
| Q4 25 | $791.2M | $850.6M | ||
| Q3 25 | $787.2M | $832.6M | ||
| Q2 25 | $790.3M | $837.2M | ||
| Q1 25 | $785.5M | $823.1M | ||
| Q4 24 | $775.7M | $893.3M | ||
| Q3 24 | $745.9M | $867.9M | ||
| Q2 24 | $768.6M | $882.0M | ||
| Q1 24 | $774.6M | $906.0M |
负债/权益比ATECOFIX
| Q4 25 | 45.54× | — | ||
| Q3 25 | 48.64× | 0.36× | ||
| Q2 25 | 23.30× | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | 30.34× | 0.22× | ||
| Q1 24 | 13.70× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $20.7M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $7.7M | $16.8M |
| 自由现金流率自由现金流/营收 | 3.6% | 7.6% |
| 资本支出强度资本支出/营收 | 6.1% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $2.8M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流ATECOFIX
| Q4 25 | $20.7M | $27.7M | ||
| Q3 25 | $14.0M | $12.4M | ||
| Q2 25 | $15.5M | $11.6M | ||
| Q1 25 | $-5.0M | $-18.4M | ||
| Q4 24 | $10.5M | $23.7M | ||
| Q3 24 | $-5.3M | $11.7M | ||
| Q2 24 | $-11.4M | $9.0M | ||
| Q1 24 | $-38.4M | $-18.6M |
自由现金流ATECOFIX
| Q4 25 | $7.7M | $16.8M | ||
| Q3 25 | $4.8M | $2.5M | ||
| Q2 25 | $5.2M | $4.5M | ||
| Q1 25 | $-15.0M | $-25.1M | ||
| Q4 24 | $8.5M | $15.2M | ||
| Q3 24 | $-21.2M | $6.3M | ||
| Q2 24 | $-45.5M | $-360.0K | ||
| Q1 24 | $-69.8M | $-29.1M |
自由现金流率ATECOFIX
| Q4 25 | 3.6% | 7.6% | ||
| Q3 25 | 2.4% | 1.2% | ||
| Q2 25 | 2.8% | 2.2% | ||
| Q1 25 | -8.9% | -13.0% | ||
| Q4 24 | 4.8% | 7.0% | ||
| Q3 24 | -14.1% | 3.2% | ||
| Q2 24 | -31.3% | -0.2% | ||
| Q1 24 | -50.4% | -15.4% |
资本支出强度ATECOFIX
| Q4 25 | 6.1% | 4.9% | ||
| Q3 25 | 4.7% | 4.8% | ||
| Q2 25 | 5.6% | 3.5% | ||
| Q1 25 | 5.9% | 3.5% | ||
| Q4 24 | 1.1% | 4.0% | ||
| Q3 24 | 10.5% | 2.7% | ||
| Q2 24 | 23.4% | 4.7% | ||
| Q1 24 | 22.6% | 5.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATEC
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
